Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The CBFA2T3::GLIS2 (CG) fusion protein causes aggressive pediatric acute megakaryoblastic leukemia (AMKL). Although dysregulated molecular pathways in AMKL have been identified, their role in early pre-leukemic transformation remains poorly understood. We developed a disease model utilizing genetically modified human induced pluripotent stem cells (hiPSC) physiologically and conditionally expressing CG. Using in vitro differentiation and single-cell multi-omics, we captured the impact of oncogene activity on gene-regulatory networks during hematopoiesis. We discovered that CG interferes with myelopoiesis through two alternative routes: by locking aberrant megakaryocyte progenitors (aMKP) in a proliferative state, or by impeding differentiation of aberrant megakaryocytes (aMK). Transcriptionally and functionally, aMKPs mimic CG-AMKL cells and establish a self-renewal network with co-factors GATA2, ERG, and DLX3. In contrast, aMKs partially sustain regulators of MK maturation but fail to complete differentiation due to repression of factors like NFE2, SPI1, GATA1 and LYL1. These insights may inform new strategies for targeting AMKL cell states.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391542PMC
http://dx.doi.org/10.1038/s42003-025-08730-4DOI Listing

Publication Analysis

Top Keywords

acute megakaryoblastic
8
megakaryoblastic leukemia
8
stem cell
4
differentiation
4
cell differentiation
4
differentiation model
4
model reveals
4
reveals alternative
4
alternative fates
4
fates cbfa2t3glis2-driven
4

Similar Publications

The CBFA2T3::GLIS2 (CG) fusion protein causes aggressive pediatric acute megakaryoblastic leukemia (AMKL). Although dysregulated molecular pathways in AMKL have been identified, their role in early pre-leukemic transformation remains poorly understood. We developed a disease model utilizing genetically modified human induced pluripotent stem cells (hiPSC) physiologically and conditionally expressing CG.

View Article and Find Full Text PDF

Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.

Leukemia

August 2025

Key Laboratory of Pediatric Hematology & Oncology of the Ministry of Health of China, Department of Hematology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

View Article and Find Full Text PDF

Background: Transient abnormal myelopoiesis (TAM) is a transient abnormal leukemoid reaction that occurs in approximately 5-10% of Down syndrome cases. TAM is typically self-limiting, however, it can be life-threatening because of severe pulmonary or hepatic complications. Approximately 20% of these patients develop acute megakaryoblastic leukemia after remission by the age of 4 years.

View Article and Find Full Text PDF